nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—ABCG2—Leflunomide—systemic scleroderma	0.122	0.154	CbGbCtD
Vismodegib—CYP2C8—Mometasone—systemic scleroderma	0.101	0.127	CbGbCtD
Vismodegib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0756	0.0953	CbGbCtD
Vismodegib—ALB—Captopril—systemic scleroderma	0.0662	0.0834	CbGbCtD
Vismodegib—ALB—Mycophenolate mofetil—systemic scleroderma	0.0521	0.0657	CbGbCtD
Vismodegib—ABCB1—Lisinopril—systemic scleroderma	0.0462	0.0583	CbGbCtD
Vismodegib—CYP2C9—Leflunomide—systemic scleroderma	0.0455	0.0573	CbGbCtD
Vismodegib—ALB—Prednisone—systemic scleroderma	0.0417	0.0525	CbGbCtD
Vismodegib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0403	0.0507	CbGbCtD
Vismodegib—ABCB1—Captopril—systemic scleroderma	0.0346	0.0436	CbGbCtD
Vismodegib—ABCG2—Methotrexate—systemic scleroderma	0.0303	0.0382	CbGbCtD
Vismodegib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0273	0.0343	CbGbCtD
Vismodegib—CYP2C19—Prednisone—systemic scleroderma	0.027	0.034	CbGbCtD
Vismodegib—ABCB1—Prednisone—systemic scleroderma	0.0218	0.0275	CbGbCtD
Vismodegib—ALB—Methotrexate—systemic scleroderma	0.0209	0.0263	CbGbCtD
Vismodegib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0163	0.0206	CbGbCtD
Vismodegib—CYP2C9—cardial valve—systemic scleroderma	0.015	0.303	CbGeAlD
Vismodegib—CYP3A4—Prednisone—systemic scleroderma	0.0131	0.0165	CbGbCtD
Vismodegib—ABCB1—Methotrexate—systemic scleroderma	0.0109	0.0138	CbGbCtD
Vismodegib—SHH—connective tissue—systemic scleroderma	0.00538	0.109	CbGeAlD
Vismodegib—SHH—skin of body—systemic scleroderma	0.00486	0.098	CbGeAlD
Vismodegib—SHH—digestive system—systemic scleroderma	0.00389	0.0784	CbGeAlD
Vismodegib—SMO—connective tissue—systemic scleroderma	0.00377	0.0759	CbGeAlD
Vismodegib—SMO—skin of body—systemic scleroderma	0.0034	0.0685	CbGeAlD
Vismodegib—SHH—lung—systemic scleroderma	0.00325	0.0655	CbGeAlD
Vismodegib—SMO—tendon—systemic scleroderma	0.00259	0.0522	CbGeAlD
Vismodegib—SMO—lung—systemic scleroderma	0.00227	0.0458	CbGeAlD
Vismodegib—Blood alkaline phosphatase increased—Mycophenolic acid—systemic scleroderma	0.00119	0.00776	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00775	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00734	CcSEcCtD
Vismodegib—Blood urea increased—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00692	CcSEcCtD
Vismodegib—Hyponatraemia—Mycophenolic acid—systemic scleroderma	0.00104	0.00677	CcSEcCtD
Vismodegib—Pain in extremity—Mycophenolic acid—systemic scleroderma	0.00103	0.00675	CcSEcCtD
Vismodegib—Weight decreased—Captopril—systemic scleroderma	0.00103	0.00671	CcSEcCtD
Vismodegib—Dysgeusia—Pentoxifylline—systemic scleroderma	0.00102	0.00668	CcSEcCtD
Vismodegib—Back pain—Pentoxifylline—systemic scleroderma	0.00101	0.0066	CcSEcCtD
Vismodegib—Muscle spasms—Pentoxifylline—systemic scleroderma	0.00101	0.00656	CcSEcCtD
Vismodegib—ORM1—lung—systemic scleroderma	0.000993	0.02	CbGeAlD
Vismodegib—Hypokalaemia—Leflunomide—systemic scleroderma	0.000987	0.00644	CcSEcCtD
Vismodegib—Breast disorder—Leflunomide—systemic scleroderma	0.00098	0.00639	CcSEcCtD
Vismodegib—Dehydration—Mycophenolic acid—systemic scleroderma	0.000962	0.00627	CcSEcCtD
Vismodegib—ABCB1—blood vessel—systemic scleroderma	0.000948	0.0191	CbGeAlD
Vismodegib—Abdominal pain upper—Mycophenolic acid—systemic scleroderma	0.000945	0.00616	CcSEcCtD
Vismodegib—Hypokalaemia—Mycophenolic acid—systemic scleroderma	0.000942	0.00614	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Mycophenolate mofetil—systemic scleroderma	0.000939	0.00612	CcSEcCtD
Vismodegib—Hyponatraemia—Lisinopril—systemic scleroderma	0.000936	0.0061	CcSEcCtD
Vismodegib—Breast disorder—Mycophenolic acid—systemic scleroderma	0.000935	0.0061	CcSEcCtD
Vismodegib—Pain in extremity—Lisinopril—systemic scleroderma	0.000932	0.00608	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Mycophenolic acid—systemic scleroderma	0.000932	0.00608	CcSEcCtD
Vismodegib—Myalgia—Pentoxifylline—systemic scleroderma	0.00089	0.00581	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.000884	0.00577	CcSEcCtD
Vismodegib—Back pain—Mometasone—systemic scleroderma	0.000873	0.00569	CcSEcCtD
Vismodegib—Amenorrhoea—Prednisone—systemic scleroderma	0.000868	0.00566	CcSEcCtD
Vismodegib—Dehydration—Lisinopril—systemic scleroderma	0.000867	0.00565	CcSEcCtD
Vismodegib—Weight decreased—Leflunomide—systemic scleroderma	0.000848	0.00553	CcSEcCtD
Vismodegib—Breast disorder—Lisinopril—systemic scleroderma	0.000842	0.00549	CcSEcCtD
Vismodegib—CYP2C19—digestive system—systemic scleroderma	0.000839	0.0169	CbGeAlD
Vismodegib—Skin disorder—Pentoxifylline—systemic scleroderma	0.000829	0.00541	CcSEcCtD
Vismodegib—Hyponatraemia—Mycophenolate mofetil—systemic scleroderma	0.00082	0.00535	CcSEcCtD
Vismodegib—Weight decreased—Mycophenolic acid—systemic scleroderma	0.000809	0.00528	CcSEcCtD
Vismodegib—Alopecia—Captopril—systemic scleroderma	0.000805	0.00525	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Pentoxifylline—systemic scleroderma	0.000778	0.00507	CcSEcCtD
Vismodegib—Dysgeusia—Captopril—systemic scleroderma	0.000776	0.00506	CcSEcCtD
Vismodegib—Arthralgia—Mometasone—systemic scleroderma	0.000768	0.00501	CcSEcCtD
Vismodegib—Myalgia—Mometasone—systemic scleroderma	0.000768	0.00501	CcSEcCtD
Vismodegib—Dehydration—Mycophenolate mofetil—systemic scleroderma	0.00076	0.00495	CcSEcCtD
Vismodegib—Dyspepsia—Pentoxifylline—systemic scleroderma	0.000751	0.0049	CcSEcCtD
Vismodegib—Hypokalaemia—Mycophenolate mofetil—systemic scleroderma	0.000743	0.00485	CcSEcCtD
Vismodegib—Decreased appetite—Pentoxifylline—systemic scleroderma	0.000742	0.00484	CcSEcCtD
Vismodegib—Connective tissue disorder—Leflunomide—systemic scleroderma	0.000737	0.00481	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Mycophenolate mofetil—systemic scleroderma	0.000735	0.00479	CcSEcCtD
Vismodegib—Constipation—Pentoxifylline—systemic scleroderma	0.00073	0.00476	CcSEcCtD
Vismodegib—Weight decreased—Lisinopril—systemic scleroderma	0.000729	0.00475	CcSEcCtD
Vismodegib—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.000704	0.00459	CcSEcCtD
Vismodegib—Alopecia—Azathioprine—systemic scleroderma	0.000702	0.00458	CcSEcCtD
Vismodegib—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.000698	0.00455	CcSEcCtD
Vismodegib—Myalgia—Captopril—systemic scleroderma	0.000675	0.0044	CcSEcCtD
Vismodegib—Arthralgia—Captopril—systemic scleroderma	0.000675	0.0044	CcSEcCtD
Vismodegib—Abdominal pain—Pentoxifylline—systemic scleroderma	0.000675	0.0044	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Methotrexate—systemic scleroderma	0.000674	0.00439	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.000671	0.00437	CcSEcCtD
Vismodegib—Alopecia—Leflunomide—systemic scleroderma	0.000663	0.00432	CcSEcCtD
Vismodegib—Malnutrition—Leflunomide—systemic scleroderma	0.000653	0.00426	CcSEcCtD
Vismodegib—CYP2C9—digestive system—systemic scleroderma	0.000651	0.0131	CbGeAlD
Vismodegib—Dyspepsia—Mometasone—systemic scleroderma	0.000648	0.00423	CcSEcCtD
Vismodegib—Decreased appetite—Mometasone—systemic scleroderma	0.00064	0.00417	CcSEcCtD
Vismodegib—Dysgeusia—Leflunomide—systemic scleroderma	0.00064	0.00417	CcSEcCtD
Vismodegib—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.000639	0.00416	CcSEcCtD
Vismodegib—Fatigue—Mometasone—systemic scleroderma	0.000635	0.00414	CcSEcCtD
Vismodegib—Alopecia—Mycophenolic acid—systemic scleroderma	0.000633	0.00412	CcSEcCtD
Vismodegib—Back pain—Leflunomide—systemic scleroderma	0.000632	0.00412	CcSEcCtD
Vismodegib—Pain—Mometasone—systemic scleroderma	0.00063	0.00411	CcSEcCtD
Vismodegib—Muscle spasms—Leflunomide—systemic scleroderma	0.000628	0.00409	CcSEcCtD
Vismodegib—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000623	0.00406	CcSEcCtD
Vismodegib—Asthenia—Pentoxifylline—systemic scleroderma	0.000612	0.00399	CcSEcCtD
Vismodegib—Pruritus—Pentoxifylline—systemic scleroderma	0.000604	0.00394	CcSEcCtD
Vismodegib—Back pain—Mycophenolic acid—systemic scleroderma	0.000603	0.00393	CcSEcCtD
Vismodegib—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000602	0.00393	CcSEcCtD
Vismodegib—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.000599	0.00391	CcSEcCtD
Vismodegib—ABCG2—lung—systemic scleroderma	0.000595	0.012	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000589	0.00384	CcSEcCtD
Vismodegib—Arthralgia—Azathioprine—systemic scleroderma	0.000589	0.00384	CcSEcCtD
Vismodegib—Myalgia—Azathioprine—systemic scleroderma	0.000589	0.00384	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000585	0.00381	CcSEcCtD
Vismodegib—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000584	0.00381	CcSEcCtD
Vismodegib—Abdominal pain—Mometasone—systemic scleroderma	0.000582	0.0038	CcSEcCtD
Vismodegib—Alopecia—Lisinopril—systemic scleroderma	0.00057	0.00371	CcSEcCtD
Vismodegib—Dyspepsia—Captopril—systemic scleroderma	0.000569	0.00371	CcSEcCtD
Vismodegib—Decreased appetite—Captopril—systemic scleroderma	0.000562	0.00367	CcSEcCtD
Vismodegib—Malnutrition—Lisinopril—systemic scleroderma	0.000561	0.00366	CcSEcCtD
Vismodegib—Fatigue—Captopril—systemic scleroderma	0.000558	0.00364	CcSEcCtD
Vismodegib—Arthralgia—Leflunomide—systemic scleroderma	0.000556	0.00363	CcSEcCtD
Vismodegib—Myalgia—Leflunomide—systemic scleroderma	0.000556	0.00363	CcSEcCtD
Vismodegib—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000555	0.00362	CcSEcCtD
Vismodegib—Constipation—Captopril—systemic scleroderma	0.000553	0.00361	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000552	0.0036	CcSEcCtD
Vismodegib—Dysgeusia—Lisinopril—systemic scleroderma	0.00055	0.00358	CcSEcCtD
Vismodegib—Skin disorder—Azathioprine—systemic scleroderma	0.000548	0.00358	CcSEcCtD
Vismodegib—Back pain—Lisinopril—systemic scleroderma	0.000543	0.00354	CcSEcCtD
Vismodegib—Vomiting—Pentoxifylline—systemic scleroderma	0.000543	0.00354	CcSEcCtD
Vismodegib—Muscle spasms—Lisinopril—systemic scleroderma	0.00054	0.00352	CcSEcCtD
Vismodegib—Rash—Pentoxifylline—systemic scleroderma	0.000538	0.00351	CcSEcCtD
Vismodegib—Dermatitis—Pentoxifylline—systemic scleroderma	0.000538	0.00351	CcSEcCtD
Vismodegib—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000531	0.00346	CcSEcCtD
Vismodegib—Myalgia—Mycophenolic acid—systemic scleroderma	0.000531	0.00346	CcSEcCtD
Vismodegib—Gastrointestinal pain—Captopril—systemic scleroderma	0.000529	0.00345	CcSEcCtD
Vismodegib—Asthenia—Mometasone—systemic scleroderma	0.000528	0.00345	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000527	0.00344	CcSEcCtD
Vismodegib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000523	0.00341	CcSEcCtD
Vismodegib—Pruritus—Mometasone—systemic scleroderma	0.000521	0.0034	CcSEcCtD
Vismodegib—Skin disorder—Leflunomide—systemic scleroderma	0.000518	0.00338	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000514	0.00335	CcSEcCtD
Vismodegib—Abdominal pain—Captopril—systemic scleroderma	0.000511	0.00333	CcSEcCtD
Vismodegib—Nausea—Pentoxifylline—systemic scleroderma	0.000507	0.00331	CcSEcCtD
Vismodegib—Diarrhoea—Mometasone—systemic scleroderma	0.000504	0.00329	CcSEcCtD
Vismodegib—Hypokalaemia—Prednisone—systemic scleroderma	0.000504	0.00328	CcSEcCtD
Vismodegib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000499	0.00325	CcSEcCtD
Vismodegib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000499	0.00325	CcSEcCtD
Vismodegib—CYP3A4—digestive system—systemic scleroderma	0.000496	0.01	CbGeAlD
Vismodegib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000494	0.00322	CcSEcCtD
Vismodegib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000492	0.00321	CcSEcCtD
Vismodegib—SHH—Validated transcriptional targets of TAp63 isoforms—GDF15—systemic scleroderma	0.000489	0.14	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000487	0.00318	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000486	0.00317	CcSEcCtD
Vismodegib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000482	0.00314	CcSEcCtD
Vismodegib—Myalgia—Lisinopril—systemic scleroderma	0.000478	0.00312	CcSEcCtD
Vismodegib—Arthralgia—Lisinopril—systemic scleroderma	0.000478	0.00312	CcSEcCtD
Vismodegib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000476	0.0031	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000475	0.00309	CcSEcCtD
Vismodegib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000473	0.00308	CcSEcCtD
Vismodegib—Dyspepsia—Leflunomide—systemic scleroderma	0.000469	0.00306	CcSEcCtD
Vismodegib—Vomiting—Mometasone—systemic scleroderma	0.000468	0.00305	CcSEcCtD
Vismodegib—Rash—Mometasone—systemic scleroderma	0.000464	0.00303	CcSEcCtD
Vismodegib—Asthenia—Captopril—systemic scleroderma	0.000464	0.00303	CcSEcCtD
Vismodegib—Dermatitis—Mometasone—systemic scleroderma	0.000464	0.00302	CcSEcCtD
Vismodegib—Decreased appetite—Leflunomide—systemic scleroderma	0.000463	0.00302	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000463	0.00302	CcSEcCtD
Vismodegib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000462	0.00301	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00046	0.003	CcSEcCtD
Vismodegib—Fatigue—Leflunomide—systemic scleroderma	0.00046	0.003	CcSEcCtD
Vismodegib—Pruritus—Captopril—systemic scleroderma	0.000458	0.00298	CcSEcCtD
Vismodegib—Constipation—Leflunomide—systemic scleroderma	0.000456	0.00297	CcSEcCtD
Vismodegib—Pain—Leflunomide—systemic scleroderma	0.000456	0.00297	CcSEcCtD
Vismodegib—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000448	0.00292	CcSEcCtD
Vismodegib—Abdominal pain—Azathioprine—systemic scleroderma	0.000446	0.00291	CcSEcCtD
Vismodegib—Skin disorder—Lisinopril—systemic scleroderma	0.000445	0.0029	CcSEcCtD
Vismodegib—Diarrhoea—Captopril—systemic scleroderma	0.000443	0.00289	CcSEcCtD
Vismodegib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000442	0.00288	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000439	0.00286	CcSEcCtD
Vismodegib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000439	0.00286	CcSEcCtD
Vismodegib—Nausea—Mometasone—systemic scleroderma	0.000437	0.00285	CcSEcCtD
Vismodegib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000436	0.00284	CcSEcCtD
Vismodegib—Pain—Mycophenolic acid—systemic scleroderma	0.000435	0.00284	CcSEcCtD
Vismodegib—Constipation—Mycophenolic acid—systemic scleroderma	0.000435	0.00284	CcSEcCtD
Vismodegib—Weight decreased—Prednisone—systemic scleroderma	0.000433	0.00282	CcSEcCtD
Vismodegib—Abdominal pain—Leflunomide—systemic scleroderma	0.000421	0.00275	CcSEcCtD
Vismodegib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000419	0.00273	CcSEcCtD
Vismodegib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000419	0.00273	CcSEcCtD
Vismodegib—Breast disorder—Methotrexate—systemic scleroderma	0.000418	0.00273	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000417	0.00272	CcSEcCtD
Vismodegib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000416	0.00271	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000416	0.00271	CcSEcCtD
Vismodegib—Vomiting—Captopril—systemic scleroderma	0.000411	0.00268	CcSEcCtD
Vismodegib—Rash—Captopril—systemic scleroderma	0.000408	0.00266	CcSEcCtD
Vismodegib—Dermatitis—Captopril—systemic scleroderma	0.000408	0.00266	CcSEcCtD
Vismodegib—Dyspepsia—Lisinopril—systemic scleroderma	0.000403	0.00263	CcSEcCtD
Vismodegib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000402	0.00262	CcSEcCtD
Vismodegib—Decreased appetite—Lisinopril—systemic scleroderma	0.000398	0.0026	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000396	0.00258	CcSEcCtD
Vismodegib—Fatigue—Lisinopril—systemic scleroderma	0.000395	0.00258	CcSEcCtD
Vismodegib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000394	0.00257	CcSEcCtD
Vismodegib—Pain—Lisinopril—systemic scleroderma	0.000392	0.00255	CcSEcCtD
Vismodegib—Constipation—Lisinopril—systemic scleroderma	0.000392	0.00255	CcSEcCtD
Vismodegib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00039	0.00254	CcSEcCtD
Vismodegib—Diarrhoea—Azathioprine—systemic scleroderma	0.000386	0.00252	CcSEcCtD
Vismodegib—Nausea—Captopril—systemic scleroderma	0.000384	0.00251	CcSEcCtD
Vismodegib—SHH—Differentiation Pathway—CSF1—systemic scleroderma	0.000383	0.11	CbGpPWpGaD
Vismodegib—Asthenia—Leflunomide—systemic scleroderma	0.000383	0.00249	CcSEcCtD
Vismodegib—Pruritus—Leflunomide—systemic scleroderma	0.000377	0.00246	CcSEcCtD
Vismodegib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000376	0.00245	CcSEcCtD
Vismodegib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000375	0.00244	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000366	0.00238	CcSEcCtD
Vismodegib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000365	0.00238	CcSEcCtD
Vismodegib—Diarrhoea—Leflunomide—systemic scleroderma	0.000365	0.00238	CcSEcCtD
Vismodegib—Abdominal pain—Lisinopril—systemic scleroderma	0.000362	0.00236	CcSEcCtD
Vismodegib—Pruritus—Mycophenolic acid—systemic scleroderma	0.00036	0.00235	CcSEcCtD
Vismodegib—Vomiting—Azathioprine—systemic scleroderma	0.000359	0.00234	CcSEcCtD
Vismodegib—Rash—Azathioprine—systemic scleroderma	0.000356	0.00232	CcSEcCtD
Vismodegib—Dermatitis—Azathioprine—systemic scleroderma	0.000356	0.00232	CcSEcCtD
Vismodegib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000353	0.0023	CcSEcCtD
Vismodegib—ABCB1—digestive system—systemic scleroderma	0.000351	0.00708	CbGeAlD
Vismodegib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000349	0.00227	CcSEcCtD
Vismodegib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000348	0.00227	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000347	0.00226	CcSEcCtD
Vismodegib—Pain—Mycophenolate mofetil—systemic scleroderma	0.000343	0.00224	CcSEcCtD
Vismodegib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000343	0.00224	CcSEcCtD
Vismodegib—Vomiting—Leflunomide—systemic scleroderma	0.000339	0.00221	CcSEcCtD
Vismodegib—Alopecia—Prednisone—systemic scleroderma	0.000338	0.00221	CcSEcCtD
Vismodegib—Rash—Leflunomide—systemic scleroderma	0.000336	0.00219	CcSEcCtD
Vismodegib—Dermatitis—Leflunomide—systemic scleroderma	0.000336	0.00219	CcSEcCtD
Vismodegib—Nausea—Azathioprine—systemic scleroderma	0.000335	0.00219	CcSEcCtD
Vismodegib—Malnutrition—Prednisone—systemic scleroderma	0.000333	0.00217	CcSEcCtD
Vismodegib—Asthenia—Lisinopril—systemic scleroderma	0.000329	0.00214	CcSEcCtD
Vismodegib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000328	0.00214	CcSEcCtD
Vismodegib—Pruritus—Lisinopril—systemic scleroderma	0.000324	0.00211	CcSEcCtD
Vismodegib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000323	0.00211	CcSEcCtD
Vismodegib—Rash—Mycophenolic acid—systemic scleroderma	0.000321	0.00209	CcSEcCtD
Vismodegib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00032	0.00209	CcSEcCtD
Vismodegib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000317	0.00207	CcSEcCtD
Vismodegib—Nausea—Leflunomide—systemic scleroderma	0.000317	0.00206	CcSEcCtD
Vismodegib—Diarrhoea—Lisinopril—systemic scleroderma	0.000313	0.00204	CcSEcCtD
Vismodegib—Nausea—Mycophenolic acid—systemic scleroderma	0.000302	0.00197	CcSEcCtD
Vismodegib—SHH—Hair Follicle Development: Induction (Part 1 of 3)—CTGF—systemic scleroderma	0.000294	0.0846	CbGpPWpGaD
Vismodegib—ABCB1—lung—systemic scleroderma	0.000293	0.00591	CbGeAlD
Vismodegib—Vomiting—Lisinopril—systemic scleroderma	0.000291	0.0019	CcSEcCtD
Vismodegib—Rash—Lisinopril—systemic scleroderma	0.000289	0.00188	CcSEcCtD
Vismodegib—Dermatitis—Lisinopril—systemic scleroderma	0.000289	0.00188	CcSEcCtD
Vismodegib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000288	0.00188	CcSEcCtD
Vismodegib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000284	0.00185	CcSEcCtD
Vismodegib—Arthralgia—Prednisone—systemic scleroderma	0.000284	0.00185	CcSEcCtD
Vismodegib—Myalgia—Prednisone—systemic scleroderma	0.000284	0.00185	CcSEcCtD
Vismodegib—Alopecia—Methotrexate—systemic scleroderma	0.000283	0.00184	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000282	0.00184	CcSEcCtD
Vismodegib—SMO—Hair Follicle Development: Induction (Part 1 of 3)—CTGF—systemic scleroderma	0.000279	0.0802	CbGpPWpGaD
Vismodegib—Malnutrition—Methotrexate—systemic scleroderma	0.000279	0.00182	CcSEcCtD
Vismodegib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00179	CcSEcCtD
Vismodegib—Dysgeusia—Methotrexate—systemic scleroderma	0.000273	0.00178	CcSEcCtD
Vismodegib—Nausea—Lisinopril—systemic scleroderma	0.000272	0.00177	CcSEcCtD
Vismodegib—Back pain—Methotrexate—systemic scleroderma	0.00027	0.00176	CcSEcCtD
Vismodegib—Nervous system disorder—Prednisone—systemic scleroderma	0.000267	0.00174	CcSEcCtD
Vismodegib—Skin disorder—Prednisone—systemic scleroderma	0.000264	0.00172	CcSEcCtD
Vismodegib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000255	0.00166	CcSEcCtD
Vismodegib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000253	0.00165	CcSEcCtD
Vismodegib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000253	0.00165	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000248	0.00162	CcSEcCtD
Vismodegib—Dyspepsia—Prednisone—systemic scleroderma	0.00024	0.00156	CcSEcCtD
Vismodegib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000238	0.00155	CcSEcCtD
Vismodegib—Myalgia—Methotrexate—systemic scleroderma	0.000237	0.00155	CcSEcCtD
Vismodegib—Arthralgia—Methotrexate—systemic scleroderma	0.000237	0.00155	CcSEcCtD
Vismodegib—Decreased appetite—Prednisone—systemic scleroderma	0.000237	0.00154	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000236	0.00154	CcSEcCtD
Vismodegib—Fatigue—Prednisone—systemic scleroderma	0.000235	0.00153	CcSEcCtD
Vismodegib—Constipation—Prednisone—systemic scleroderma	0.000233	0.00152	CcSEcCtD
Vismodegib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000223	0.00145	CcSEcCtD
Vismodegib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000222	0.00145	CcSEcCtD
Vismodegib—Skin disorder—Methotrexate—systemic scleroderma	0.000221	0.00144	CcSEcCtD
Vismodegib—Abdominal pain—Prednisone—systemic scleroderma	0.000215	0.0014	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000207	0.00135	CcSEcCtD
Vismodegib—Dyspepsia—Methotrexate—systemic scleroderma	0.0002	0.0013	CcSEcCtD
Vismodegib—Decreased appetite—Methotrexate—systemic scleroderma	0.000198	0.00129	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000196	0.00128	CcSEcCtD
Vismodegib—Fatigue—Methotrexate—systemic scleroderma	0.000196	0.00128	CcSEcCtD
Vismodegib—Asthenia—Prednisone—systemic scleroderma	0.000195	0.00127	CcSEcCtD
Vismodegib—Pain—Methotrexate—systemic scleroderma	0.000194	0.00127	CcSEcCtD
Vismodegib—Pruritus—Prednisone—systemic scleroderma	0.000193	0.00126	CcSEcCtD
Vismodegib—Diarrhoea—Prednisone—systemic scleroderma	0.000186	0.00121	CcSEcCtD
Vismodegib—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000186	0.00121	CcSEcCtD
Vismodegib—Abdominal pain—Methotrexate—systemic scleroderma	0.00018	0.00117	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000178	0.0511	CbGpPWpGaD
Vismodegib—Vomiting—Prednisone—systemic scleroderma	0.000173	0.00113	CcSEcCtD
Vismodegib—Rash—Prednisone—systemic scleroderma	0.000172	0.00112	CcSEcCtD
Vismodegib—Dermatitis—Prednisone—systemic scleroderma	0.000171	0.00112	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000169	0.0485	CbGpPWpGaD
Vismodegib—Asthenia—Methotrexate—systemic scleroderma	0.000163	0.00106	CcSEcCtD
Vismodegib—Nausea—Prednisone—systemic scleroderma	0.000162	0.00105	CcSEcCtD
Vismodegib—Pruritus—Methotrexate—systemic scleroderma	0.000161	0.00105	CcSEcCtD
Vismodegib—Diarrhoea—Methotrexate—systemic scleroderma	0.000156	0.00101	CcSEcCtD
Vismodegib—Vomiting—Methotrexate—systemic scleroderma	0.000145	0.000943	CcSEcCtD
Vismodegib—Rash—Methotrexate—systemic scleroderma	0.000143	0.000935	CcSEcCtD
Vismodegib—Dermatitis—Methotrexate—systemic scleroderma	0.000143	0.000934	CcSEcCtD
Vismodegib—Nausea—Methotrexate—systemic scleroderma	0.000135	0.000881	CcSEcCtD
Vismodegib—SHH—Dopaminergic Neurogenesis—TGFB1—systemic scleroderma	0.000111	0.0319	CbGpPWpGaD
Vismodegib—SHH—Differentiation Pathway—TGFB1—systemic scleroderma	7.62e-05	0.0219	CbGpPWpGaD
Vismodegib—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	7.47e-05	0.0215	CbGpPWpGaD
Vismodegib—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	5.82e-05	0.0167	CbGpPWpGaD
Vismodegib—SHH—Ectoderm Differentiation—CCL2—systemic scleroderma	5.55e-05	0.016	CbGpPWpGaD
Vismodegib—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	4.96e-05	0.0143	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—CSF1—systemic scleroderma	4.36e-05	0.0125	CbGpPWpGaD
Vismodegib—ALB—Platelet degranulation—SELP—systemic scleroderma	3.87e-05	0.0111	CbGpPWpGaD
Vismodegib—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	3.73e-05	0.0107	CbGpPWpGaD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	3.69e-05	0.0106	CbGpPWpGaD
Vismodegib—SHH—Disease—SMAD7—systemic scleroderma	3.52e-05	0.0101	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	3.49e-05	0.01	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—RHOB—systemic scleroderma	3.23e-05	0.00928	CbGpPWpGaD
Vismodegib—SHH—Disease—TGFBI—systemic scleroderma	3.22e-05	0.00926	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—EDN1—systemic scleroderma	3.21e-05	0.00923	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—RHOB—systemic scleroderma	3.06e-05	0.0088	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—EDN1—systemic scleroderma	3.04e-05	0.00875	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL13—systemic scleroderma	2.58e-05	0.00742	CbGpPWpGaD
Vismodegib—SHH—Disease—HSPG2—systemic scleroderma	2.57e-05	0.00738	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.52e-05	0.00725	CbGpPWpGaD
Vismodegib—SHH—Disease—CSK—systemic scleroderma	2.48e-05	0.00713	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SMAD7—systemic scleroderma	2.47e-05	0.00709	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.39e-05	0.00687	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SMAD7—systemic scleroderma	2.34e-05	0.00672	CbGpPWpGaD
Vismodegib—SHH—Disease—CD247—systemic scleroderma	2.33e-05	0.0067	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	2.29e-05	0.00658	CbGpPWpGaD
Vismodegib—SHH—GPCR ligand binding—CCL2—systemic scleroderma	2.2e-05	0.00631	CbGpPWpGaD
Vismodegib—SMO—GPCR ligand binding—CCL2—systemic scleroderma	2.08e-05	0.00598	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	2.08e-05	0.00597	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—RHOB—systemic scleroderma	1.91e-05	0.00548	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	1.89e-05	0.00542	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—RHOB—systemic scleroderma	1.81e-05	0.0052	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	1.81e-05	0.0052	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HSPG2—systemic scleroderma	1.8e-05	0.00517	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CSK—systemic scleroderma	1.74e-05	0.00499	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	1.72e-05	0.00493	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	1.71e-05	0.00491	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HSPG2—systemic scleroderma	1.7e-05	0.0049	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—EDN1—systemic scleroderma	1.65e-05	0.00474	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CSK—systemic scleroderma	1.65e-05	0.00473	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	1.62e-05	0.00467	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	1.61e-05	0.00464	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	1.6e-05	0.00461	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—EDN1—systemic scleroderma	1.56e-05	0.00449	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—CCL2—systemic scleroderma	1.47e-05	0.00423	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	1.46e-05	0.0042	CbGpPWpGaD
Vismodegib—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	1.37e-05	0.00394	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	1.17e-05	0.00336	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CCL2—systemic scleroderma	1.13e-05	0.00324	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—IL1B—systemic scleroderma	1.12e-05	0.00321	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CCL2—systemic scleroderma	1.07e-05	0.00307	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—EDN1—systemic scleroderma	9.74e-06	0.0028	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EDN1—systemic scleroderma	9.23e-06	0.00265	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	8.86e-06	0.00255	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—SELP—systemic scleroderma	8.85e-06	0.00254	CbGpPWpGaD
Vismodegib—SHH—Disease—NOS3—systemic scleroderma	8.47e-06	0.00244	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	8.47e-06	0.00243	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—RHOB—systemic scleroderma	8.26e-06	0.00237	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—CSK—systemic scleroderma	7.52e-06	0.00216	CbGpPWpGaD
Vismodegib—ALB—Platelet degranulation—TGFB1—systemic scleroderma	7.43e-06	0.00214	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.13e-06	0.00205	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.09e-06	0.00204	CbGpPWpGaD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	7.08e-06	0.00204	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—ITGAM—systemic scleroderma	7.07e-06	0.00203	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCL2—systemic scleroderma	6.66e-06	0.00191	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	6.58e-06	0.00189	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.37e-06	0.00183	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCL2—systemic scleroderma	6.31e-06	0.00181	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NOS3—systemic scleroderma	5.93e-06	0.00171	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.81e-06	0.00167	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NOS3—systemic scleroderma	5.62e-06	0.00162	CbGpPWpGaD
Vismodegib—SHH—Disease—TGFB1—systemic scleroderma	5.6e-06	0.00161	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.41e-06	0.00155	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.38e-06	0.00155	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—HSPG2—systemic scleroderma	5.12e-06	0.00147	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.83e-06	0.00139	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MMP9—systemic scleroderma	4.76e-06	0.00137	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MMP9—systemic scleroderma	4.51e-06	0.0013	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.4e-06	0.00126	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TGFB1—systemic scleroderma	3.92e-06	0.00113	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CTGF—systemic scleroderma	3.88e-06	0.00112	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TGFB1—systemic scleroderma	3.72e-06	0.00107	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—MMP1—systemic scleroderma	3.55e-06	0.00102	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.3e-06	0.000948	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.25e-06	0.000933	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	3.18e-06	0.000913	CbGpPWpGaD
Vismodegib—ALB—Metabolism—HSPG2—systemic scleroderma	3.16e-06	0.000908	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	2.84e-06	0.000815	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.77e-06	0.000796	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	2.59e-06	0.000743	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NOS3—systemic scleroderma	2.57e-06	0.000739	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CTGF—systemic scleroderma	2.41e-06	0.000692	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CTGF—systemic scleroderma	2.39e-06	0.000688	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CTGF—systemic scleroderma	2.15e-06	0.000618	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CTGF—systemic scleroderma	2.1e-06	0.000603	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CTGF—systemic scleroderma	1.96e-06	0.000563	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.71e-06	0.00049	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TGFB1—systemic scleroderma	1.7e-06	0.000488	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—NOS3—systemic scleroderma	1.69e-06	0.000485	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.29e-06	0.000371	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NOS3—systemic scleroderma	1.05e-06	0.000301	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NOS3—systemic scleroderma	1.04e-06	0.0003	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NOS3—systemic scleroderma	9.35e-07	0.000269	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NOS3—systemic scleroderma	9.13e-07	0.000262	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NOS3—systemic scleroderma	8.53e-07	0.000245	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NOS3—systemic scleroderma	5.62e-07	0.000162	CbGpPWpGaD
